Login to Your Account

Emmaus files NDA for sickle cell therapy

By Michael Fitzhugh
Staff Writer

Thursday, September 8, 2016

Two years after an errant statistical analysis derailed Emmaus Life Sciences Inc.'s initial efforts to gain approval for its pharmaceutical-grade L-glutamine, a treatment for adults and children with sickle cell disease, the company is back on track, seeking priority review for its NDA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription